Shares of Halozyme Therapeutics (Nasdaq:HALO) were gapping down Monday morning with an open price 23.8% lower than Friday's closing price. The stock closed at $11.27 yesterday and opened today's trading at $8.59.
NEW YORK ( TheStreet) -- Shares of Halozyme Therapeutics (Nasdaq: HALO) were gapping down Monday morning with an open price 23.8% lower than Friday's closing price. The stock closed at $11.27 Friday and opened today's trading at $8.59. The average volume for Halozyme has been 912,500 shares per day over the past 30 days. Halozyme has a market cap of $1.36 billion and is part of the health care sector and drugs industry. Shares are up 18.5% year to date as of the close of trading on Friday. Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits. TheStreet Ratings rates Halozyme as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow and feeble growth in its earnings per share. You can view the full Halozyme Ratings Report. Get more investment ideas from our investment research center. Interested in other stocks that are gapping down? Get free SMS text alerts sent to you when the action happens by texting DOWN to 95370 or select from multiple alert options.